2021
DOI: 10.1177/11782234211006677
|View full text |Cite
|
Sign up to set email alerts
|

Tumour Lysis Syndrome in Occult Breast Cancer Treated With Letrozole – A Rare Occurrence. A Case Report and Review

Abstract: Tumour lysis syndrome (TLS) is a medical emergency occurring when large numbers of cancer cells rapidly undergo cell death. The resultant metabolic abnormalities results in significant morbidity and mortality. Tumour lysis syndrome most commonly occurs in 5% of haematological malignancies and is less commonly described in solid organ cancers. In breast cancer, TLS has been reported to occur both spontaneously and as a result of cancer chemotherapy, targeted therapy, or radiotherapy. However, only 1 TLS case in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 39 publications
0
4
0
Order By: Relevance
“…This biological behavior appears to be a potential risk factor for TLS. Recently, TLS was reported in a patient with occult breast cancer who was treated with letrozole (26). This case report suggests that a higher tumor burden is not always an essential predictive factor for the development of TLS.…”
Section: Discussionmentioning
confidence: 89%
“…This biological behavior appears to be a potential risk factor for TLS. Recently, TLS was reported in a patient with occult breast cancer who was treated with letrozole (26). This case report suggests that a higher tumor burden is not always an essential predictive factor for the development of TLS.…”
Section: Discussionmentioning
confidence: 89%
“…TLS has also been commonly reported in hematological malignancies but is becoming more frequently noted in solid tumors as treatments become more efficient [ 11 ]. Table 2 (modified from Watkinson and Hari Dass [ 3 ]) summarizes all reported TLS cases caused by breast cancer treatment. A total of 22 TLS cases associated with breast cancer have been reported, including three with hormone therapy only (one with tamoxifen and two with letrozole), three with hormone therapy plus a cyclin-dependent kinase 4/6 inhibitor or PIK3CA inhibitor, two with anti-HER2 therapy, nine with chemotherapy, two with radiation therapy, and three without therapy.…”
Section: Discussionmentioning
confidence: 99%
“…The table details the publication author, patient age, any tumor type and stage specifics (where reported in the publication), treatment administered, risk factors specified, and outcome. Modified from Watkinson and Hari Dass [ 3 ] TLS tumor lysis syndrome…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation